The TNNT2 antibody targets cardiac troponin T (cTnT), a key component of the troponin complex that regulates striated muscle contraction. Encoded by the TNNT2 gene, this 35-40 kDa protein is predominantly expressed in cardiac tissue and plays a critical role in calcium-dependent interactions between tropomyosin and actin filaments. As a cardiac-specific biomarker, TNNT2 is widely used in clinical diagnostics to detect myocardial injury, particularly in acute coronary syndromes like myocardial infarction. Commercially available TNNT2 antibodies (polyclonal or monoclonal) are essential tools for research and diagnostics, enabling techniques such as Western blotting, immunohistochemistry, and ELISA to quantify cTnT levels in serum or tissue samples. Beyond diagnostics, TNNT2 antibodies aid in studying genetic cardiomyopathies, as TNNT2 mutations are linked to 15-20% of familial hypertrophic cardiomyopathy cases and some dilated cardiomyopathies. These mutations often disrupt sarcomere function, leading to pathological cardiac remodeling. Antibody specificity is crucial, as cross-reactivity with skeletal muscle troponin T isoforms must be avoided. Recent advancements include high-sensitivity assays using TNNT2 antibodies for early myocardial injury detection and therapeutic monitoring. Research-grade antibodies also facilitate mechanistic studies in cardiac development, disease modeling, and drug screening.